Diversity and inter-connections in the CXCR4 chemokine receptor/ligand family: Molecular perspectives

Frontiers in Immunology

Volumn 6, Issue AUG, 2015, Pages

  Pawig, Lukas ^a   Klasen, Christina ^a   Weber, Christian ^b,c,d   Bernhagen, Jürgen ^a,e   Noels, Heidi ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

ACKR3; Chemokine; CXCL12; CXCR4; CXCR7; MIF; Signaling; Ubiquitin

Indexed keywords

BETA ARRESTIN; BETA DEFENSIN 3; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR4; G PROTEIN COUPLED RECEPTOR; GELATINASE A; GLYCOPROTEIN GP 120; MIGRATION INHIBITION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; STAT PROTEIN; STROMAL CELL DERIVED FACTOR 1; UBIQUITIN;

ANGIOGENESIS; BONE MARROW; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION ASSAY; CELL PROLIFERATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; KAPOSI SARCOMA; NEURAL STEM CELL; OLIGOMERIZATION; PROTEIN HOMEOSTASIS; REVIEW;

EID: 84941266269     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00429     Document Type: Review

References (250)

1. Doring Y, Pawig L, Weber C, Noels H. The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease. Front Physiol (2014) 5:212. doi:10.3389/fphys.2014.00212.
2. Debnath B, Xu S, Grande F, Garofalo A, Neamati N. Small molecule inhibitors of CXCR4. Theranostics (2013) 3:47-75. doi:10.7150/thno.5376.
3. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, De Vries EG, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer (2013) 49:219-30. doi:10.1016/j.ejca.2012.05.005.
4. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med (2007) 13:587-96. doi:10.1038/nm1567.
5. Saini V, Staren DM, Ziarek JJ, Nashaat ZN, Campbell EM, Volkman BF, et al. The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1 function through distinct receptor interactions. J Biol Chem (2011) 286:33466-77. doi:10.1074/jbc. M111.233742.
6. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem (2005) 280:35760-6. doi:10.1074/jbc. M508234200.
7. Tarnowski M, Grymula K, Liu R, Tarnowska J, Drukala J, Ratajczak J, et al. Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts. Mol Cancer Res (2010) 8:1328-43. doi:10.1158/1541-7786.MCR-10-0288.
8. Feng Z, Dubyak GR, Lederman MM, Weinberg A. Cutting edge: human beta defensin 3-a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol (2006) 177:782-6. doi:10.4049/jimmunol.177.2.782.
9. De Clercq E. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol Pharmacol (2000) 57:833-9.
10. Kledal TN, Rosenkilde MM, Coulin F, Simmons G, Johnsen AH, Alouani S, et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science (1997) 277:1656-9. doi:10.1126/science.277.5332.1656.
11. Qin L, Kufareva I, Holden LG, Wang C, Zheng Y, Zhao C, et al. Structural biology. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Science (2015) 347:1117-22. doi:10.1126/science.1261064.
12. Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, et al. International union of basic and clinical pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2014) 66:1-79. doi:10.1111/bph.12665.
13. Caruz A, Samsom M, Alonso JM, Alcami J, Baleux F, Virelizier JL, et al. Genomic organization and promoter characterization of human CXCR4 gene 1. FEBS Lett (1998) 426:271-8. doi:10.1016/S0014-5793(98)00359-7.
14. Loetscher M, Geiser T, O'reilly T, Zwahlen R, Baggiolini M, Moser B. Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J Biol Chem (1994) 269:232-7.
15. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 272:872-7. doi:10.1126/science.272.5263.872.
16. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (1996) 382:833-5. doi:10.1038/382833a0.
17. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol (2000) 18:217-42. doi:10.1146/annurev.immunol.18.1.217.
18. Rajagopalan L, Rajarathnam K. Structural basis of chemokine receptor function-a model for binding affinity and ligand selectivity. Biosci Rep (2006) 26:325-39. doi:10.1007/s10540-006-9025-9.
19. Tillmann S, Bernhagen J, Noels H. Arrest functions of the MIF ligand/receptor axes in atherogenesis. Front Immunol (2013) 4:115. doi:10.3389/fimmu.2013.00115.
20. Ulvmar MH, Hub E, Rot A. Atypical chemokine receptors. Exp Cell Res (2011) 317:556-68. doi:10.1016/j.yexcr.2011.01.012.
21. Pruenster M, Mudde L, Bombosi P, Dimitrova S, Zsak M, Middleton J, et al. The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat Immunol (2009) 10:101-8. doi:10.1038/ni.1675.
22. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res (1997) 25:3389-402. doi:10.1093/nar/25.17.3389.
23. Werner L, Guzner-Gur H, Dotan I. Involvement of CXCR4/CXCR7/CXCL12 Interactions in Inflammatory bowel disease. Theranostics (2013) 3:40-6. doi:10.7150/thno.5135.
24. Wu B, Chien EYT, Mol CD, Fenalti G, Liu W, Katritch V, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science (2010) 330:1066-71. doi:10.1126/science.1194396.
25. Kufareva I, Stephens BS, Holden LG, Qin L, Zhao C, Kawamura T, et al. Stoichiometry and geometry of the CXC chemokine receptor 4 complex with CXC ligand 12: molecular modeling and experimental validation. Proc Natl Acad Sci U S A (2014) 111:5363-72. doi:10.1073/pnas.1417037111.
26. Murphy JW, Yuan H, Kong Y, Xiong Y, Lolis EJ. Heterologous quaternary structure of CXCL12 and its relationship to the CC chemokine family. Proteins (2010) 78:1331-7. doi:10.1002/prot.22666.
27. Crichlow GV, Lubetsky JB, Leng L, Bucala R, Lolis EJ. Structural and kinetic analyses of macrophage migration inhibitory factor active site interactions. Biochemistry (2009) 48:132-9. doi:10.1021/bi8014423.
28. Marchese A, Benovic JL. Agonist-promoted ubiquitination of the G protein-coupled receptor CXCR4 mediates lysosomal sorting. J Biol Chem (2001) 276:45509-12. doi:10.1074/jbc. C100527200.
29. Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, Shinohara T, et al. Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics (1995) 28:495-500. doi:10.1006/geno.1995.1180.
30. Yu L, Cecil J, Peng S-B, Schrementi J, Kovacevic S, Paul D, et al. Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene (2006) 374:174-9. doi:10.1016/j.gene.2006.02.001.
31. Rueda P, Balabanian K, Lagane B, Staropoli I, Chow K, Levoye A, et al. The CXCL12gamma chemokine displays unprecedented structural and functional properties that make it a paradigm of chemoattractant proteins. PLoS One (2008) 3:e2543. doi:10.1371/journal.pone.0002543.
32. Laguri C, Sadir R, Rueda P, Baleux F, Gans P, Arenzana-Seisdedos F, et al. The novel CXCL12gamma isoform encodes an unstructured cationic domain which regulates bioactivity and interaction with both glycosaminoglycans and CXCR4. PLoS One (2007) 2:e1110. doi:10.1371/journal.pone.0001110.
33. Torres R, Ramirez JC. A chemokine targets the nucleus: Cxcl12-gamma isoform localizes to the nucleolus in adult mouse heart. PLoS One (2009) 4:e7570. doi:10.1371/journal.pone.0007570.
34. Stumm RK, Rummel J, Junker V, Culmsee C, Pfeiffer M, Krieglstein J, et al. A dual role for the SDF-1/CXCR4 chemokine receptor system in adult brain: isoform-selective regulation of SDF-1 expression modulates CXCR4-dependent neuronal plasticity and cerebral leukocyte recruitment after focal ischemia. J Neurosci (2002) 22:5865-78.
35. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, et al. The transcriptional landscape of the mammalian genome. Science (2005) 309:1559-63. doi:10.1126/science.1112014.
36. Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arenzana-Seisdedos F, et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J (1997) 16:6996-7007. doi:10.1093/emboj/16.23.6996.
37. Wells TN, Power CA, Lusti-Narasimhan M, Hoogewerf AJ, Cooke RM, Chung CW, et al. Selectivity and antagonism of chemokine receptors. J Leukoc Biol (1996) 59:53-60.
38. Seibert C, Veldkamp CT, Peterson FC, Chait BT, Volkman BF, Sakmar TP. Sequential tyrosine sulfation of CXCR4 by tyrosylprotein sulfotransferases. Biochemistry (2008) 47:11251-62. doi:10.1021/bi800965m.
39. Veldkamp CT, Seibert C, Peterson FC, De La Cruz NB, Haugner JC III, Basnet H, et al. Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci Signal (2008) 1:ra4. doi:10.1126/scisignal.1160755.
40. Richter R, Jochheim-Richter A, Ciuculescu F, Kollar K, Seifried E, Forssmann U, et al. Identification and characterization of circulating variants of CXCL12 from human plasma: effects on chemotaxis and mobilization of hematopoietic stem and progenitor cells. Stem Cells Dev (2014) 23:1959-74. doi:10.1089/scd.2013.0524.
41. Lambeir AM, Proost P, Durinx C, Bal G, Senten K, Augustyns K, et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem (2001) 276:29839-45. doi:10.1074/jbc. M103106200.
42. O'boyle G, Mellor P, Kirby JA, Ali S. Anti-inflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12. FASEB J (2009) 23:3906-16. doi:10.1096/fj.09-134643.
43. Shioda T, Kato H, Ohnishi Y, Tashiro K, Ikegawa M, Nakayama EE, et al. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci U S A (1998) 95:6331-6. doi:10.1073/pnas.95.11.6331.
44. De La Luz Sierra M, Yang F, Narazaki M, Salvucci O, Davis D, Yarchoan R, et al. Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity. Blood (2004) 103:2452-9. doi:10.1182/blood-2003-08-2857.
45. Herrera C, Morimoto C, Blanco J, Mallol J, Arenzana F, Lluis C, et al. Comodulation of CXCR4 and CD26 in human lymphocytes. J Biol Chem (2001) 276:19532-9. doi:10.1074/jbc. M004586200.
46. Peng H, Wu Y, Duan Z, Ciborowski P, Zheng J. Proteolytic processing of SDF-1a by matrix metalloproteinase-2 impairs CXCR4 signaling and reduces neural progenitor cell migration. Protein Cell (2012) 3:875-82. doi:10.1007/s13238-012-2092-8.
47. McQuibban GA, Butler GS, Gong J-H, Bendall L, Power C, Clark-Lewis I, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem (2001) 276:43503-8. doi:10.1074/jbc. M107736200.
48. Valenzuela-Fernández AN, Planchenault T, Baleux F, Staropoli I, Le-Barillec K, Leduc D, et al. Leukocyte elastase negatively regulates stromal cell-derived factor-1 (SDF-1)/CXCR4 binding and functions by amino-terminal processing of SDF-1 and CXCR4. J Biol Chem (2002) 277:15677-89. doi:10.1074/jbc. M111388200.
49. Delgado MB, Clark-Lewis I, Loetscher P, Langen H, Thelen M, Baggiolini M, et al. Rapid inactivation of stromal cell-derived factor-1 by cathepsin G associated with lymphocytes. Eur J Immunol (2001) 31:699-707. doi:10.1002/1521-4141(200103)31:3<699::AID-IMMU699>3.0.CO;2-6.
50. Amara A, Lorthioir O, Valenzuela A, Magerus A, Thelen M, Montes M, et al. Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. J Biol Chem (1999) 274:23916-25. doi:10.1074/jbc.274.34.23916.
51. Rueda P, Richart A, Recalde A, Gasse P, Vilar J, Guerin C, et al. Homeostatic and tissue reparation defaults in mice carrying selective genetic invalidation of CXCL12/proteoglycan interactions. Circulation (2012) 126:1882-95. doi:10.1161/CIRCULATIONAHA.112.113290.
52. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol (2003) 3:791-800. doi:10.1038/nri1200.
53. Sun HW, Bernhagen J, Bucala R, Lolis E. Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A (1996) 93:5191-6. doi:10.1073/pnas.93.11.5191.
54. Mischke R, Kleemann R, Brunner H, Bernhagen J. Cross-linking and mutational analysis of the oligomerization state of the cytokine macrophage migration inhibitory factor (MIF). FEBS Lett (1998) 427:85-90. doi:10.1016/S0014-5793(98)00400-1.
55. Philo JS, Yang TH, Labarre M. Re-examining the oligomerization state of macrophage migration inhibitory factor (MIF) in solution. Biophys Chem (2004) 108:77-87. doi:10.1016/j.bpc.2003.10.010.
56. Ouertatani-Sakouhi H, El-Turk F, Fauvet B, Cho MK, Pinar Karpinar D, Le Roy D, et al. Identification and characterization of novel classes of macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action. J Biol Chem (2010) 285:26581-98. doi:10.1074/jbc. M110.113951.
57. Israelson A, Ditsworth D, Sun S, Song S, Liang J, Hruska-Plochan M, et al. Macrophage migration inhibitory factor as a chaperone inhibiting accumulation of misfolded SOD1. Neuron (2015) 86:218-32. doi:10.1016/j.neuron.2015.02.034.
58. Vujicic M, Senerovic L, Nikolic I, Saksida T, Stosic-Grujicic S, Stojanovic I. The critical role of macrophage migration inhibitory factor in insulin activity. Cytokine (2014) 69:39-46. doi:10.1016/j.cyto.2014.05.013.
59. Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, Bucala R. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry (1994) 33:14144-55. doi:10.1021/bi00251a025.
60. Noels H, Bernhagen J, Weber C. Macrophage migration inhibitory factor: a noncanonical chemokine important in atherosclerosis. Trends Cardiovasc Med (2009) 19:76-86. doi:10.1016/j.tcm.2009.05.002.
61. Weber C, Kraemer S, Drechsler M, Lue H, Koenen RR, Kapurniotu A, et al. Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc Natl Acad Sci U S A (2008) 105:16278-83. doi:10.1073/pnas.0804017105.
62. Kraemer S, Lue H, Zernecke A, Kapurniotu A, Andreetto E, Frank R, et al. MIF-chemokine receptor interactions in atherogenesis are dependent on an N-loop-based 2-site binding mechanism. FASEB J (2011) 25:894-906. doi:10.1096/fj.10-168559.
63. Xu L, Li Y, Li D, Xu P, Tian S, Sun H, et al. Exploring the binding mechanisms of MIF to CXCR2 using theoretical approaches. Phys Chem Chem Phys (2015) 17:3370-82. doi:10.1039/c4cp05095a.
64. Thiele M, Bernhagen J. Link between macrophage migration inhibitory factor and cellular redox regulation. Antioxid Redox Signal (2005) 7:1234-48. doi:10.1089/ars.2005.7.1234.
65. Mukhopadhyay D, Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science (2007) 315:201-5. doi:10.1126/science.1127085.
66. Kimura Y, Tanaka K. Regulatory mechanisms involved in the control of ubiquitin homeostasis. J Biochem (2010) 147:793-8. doi:10.1093/jb/mvq044.
67. Roos-Mattjus P, Sistonen L. The ubiquitin-proteasome pathway. Ann Med (2004) 36:285-95. doi:10.1080/07853890310016324.
68. Majetschak M. Extracellular ubiquitin: immune modulator and endogenous opponent of damage-associated molecular pattern molecules. J Leukoc Biol (2011) 89:205-19. doi:10.1189/jlb.0510316.
69. Goldstein G, Scheid M, Hammerling U, Schlesinger DH, Niall HD, Boyse EA. Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. Proc Natl Acad Sci U S A (1975) 72:11-5. doi:10.1073/pnas.72.1.11.
70. Saini V, Marchese A, Majetschak M. CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin. J Biol Chem (2010) 285:15566-76. doi:10.1074/jbc. M110.103408.
71. Saini V, Marchese A, Tang WJ, Majetschak M. Structural determinants of ubiquitin-CXC chemokine receptor 4 interaction. J Biol Chem (2011) 286:44145-52. doi:10.1074/jbc. M111.298505.
72. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science (1998) 280:1884-8. doi:10.1126/science.280.5371.1884.
73. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 393:648-59. doi:10.1038/31405.
74. Simon-Loriere E, Galetto R, Hamoudi M, Archer J, Lefeuvre P, Martin DP, et al. Molecular mechanisms of recombination restriction in the envelope gene of the human immunodeficiency virus. PLoS Pathog (2009) 5:e1000418. doi:10.1371/journal.ppat.1000418.
75. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature (1997) 387:426-30. doi:10.1038/387426a0.
76. Checkley MA, Luttge BG, Freed EO. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol (2011) 410:582-608. doi:10.1016/j.jmb.2011.04.042.
77. Poumbourios P, El Ahmar W, McPhee DA, Kemp BE. Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure. J Virol (1995) 69:1209-18.
78. Helseth E, Olshevsky U, Furman C, Sodroski J. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol (1991) 65:2119-23.
79. Wilen CB, Tilton JC, Doms RW. HIV: cell binding and entry. Cold Spring Harb Perspect Med (2012) 2:a006866. doi:10.1101/cshperspect.a006866.
80. Olshevsky U, Helseth E, Furman C, Li J, Haseltine W, Sodroski J. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol (1990) 64:5701-7.
81. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature (2008) 455:109-13. doi:10.1038/nature07159.
82. Hartley O, Klasse PJ, Sattentau QJ, Moore JP. V3: HIV's switch-hitter. AIDS Res Hum Retroviruses (2005) 21:171-89. doi:10.1089/aid.2005.21.171.
83. Murphy PM. Viral exploitation and subversion of the immune system through chemokine mimicry. Nat Immunol (2001) 2:116-22. doi:10.1038/84214.
84. Zhou N, Luo Z, Luo J, Hall JW, Huang Z. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II. Biochemistry (2000) 39:3782-7. doi:10.1021/bi992750v.
85. Portella L, Vitale R, De Luca S, D'alterio C, Ierano C, Napolitano M, et al. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS One (2013) 8:e74548. doi:10.1371/journal.pone.0074548.
86. Harder J, Bartels J, Christophers E, Schroder JM. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem (2001) 276:5707-13. doi:10.1074/jbc. M008557200.
87. Feng Z, Dubyak GR, Jia X, Lubkowski JT, Weinberg A. Human beta-defensin-3 structure motifs that are important in CXCR4 antagonism. FEBS J (2013) 280:3365-75. doi:10.1111/febs.12328.
88. Peled A, Kollet O, Ponomaryov T, Petit I, Franitza S, Grabovsky V, et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood (2000) 95:3289-96.
89. Mazo IB, Massberg S, Von Andrian UH. Hematopoietic stem and progenitor cell trafficking. Trends Immunol (2011) 32:493-503. doi:10.1016/j.it.2011.06.011.
90. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest (2003) 111:187-96. doi:10.1172/JCI15994.
91. Lataillade JJ, Clay D, Dupuy C, Rigal S, Jasmin C, Bourin P, et al. Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival. Blood (2000) 95:756-68.
92. Lee Y, Gotoh A, Kwon H-J, You M, Kohli L, Mantel C, et al. Enhancement of intracellular signaling associated with hematopoietic progenitor cell survival in response to SDF-1/CXCL12 in synergy with other cytokines. Blood (2002) 99:4307-17. doi:10.1182/blood. V99.12.4307.
93. Eash KJ, Greenbaum AM, Gopalan PK, Link DC. CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. J Clin Invest (2010) 120:2423-31. doi:10.1172/JCI41649.
94. Devi S, Wang Y, Chew WK, Lima R, A-González N, Mattar CN, et al. Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow. J Exp Med (2013) 210:2321-36. doi:10.1084/jem.20130056.
95. Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice. Proc Natl Acad Sci U S A (1998) 95:9448-53. doi:10.1073/pnas.95.16.9448.
96. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res (2010) 16:2927-31. doi:10.1158/1078-0432.CCR-09-2329.
97. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med (2004) 10:858-64. doi:10.1038/nm1075.
98. Saxena A, Fish JE, White MD, Yu S, Smyth JW, Shaw RM, et al. Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction. Circulation (2008) 117:2224-31. doi:10.1161/CIRCULATIONAHA.107.694992.
99. Schuh A, Kroh A, Konschalla S, Liehn EA, Sobota RM, Biessen EA, et al. Myocardial regeneration by transplantation of modified endothelial progenitor cells expressing SDF-1 in a rat model. J Cell Mol Med (2012) 16:2311-20. doi:10.1111/j.1582-4934.2012.01539.x.
100. Jie W, Wang X, Zhang Y, Guo J, Kuang D, Zhu P, et al. SDF-1alpha/CXCR4 axis is involved in glucose-potentiated proliferation and chemotaxis in rat vascular smooth muscle cells. Int J Exp Pathol (2010) 91:436-44. doi:10.1111/j.1365-2613.2010.00720.x.
101. Serrano-Pertierra E, Blanco-Gelaz MA, Oliva-Nacarino P, Martínez-Camblor P, Villafani J, López-Larrea C, et al. Increased natural killer cell chemotaxis to CXCL12 in patients with multiple sclerosis. J Neuroimmunol (2015) 282:39-44. doi:10.1016/j.jneuroim.2015.03.007.
102. Olive M, Mellad JA, Beltran LE, Ma M, Cimato T, Noguchi AC, et al. p21Cip1 modulates arterial wound repair through the stromal cell-derived factor-1/CXCR4 axis in mice. J Clin Invest (2008) 118:2050-61. doi:10.1172/JCI31244.
103. Mellado M, Rodriguez-Frade JM, Manes S, Martinez-A C. Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu Rev Immunol (2001) 19:397-421. doi:10.1146/annurev.immunol.19.1.397.
104. Hadad I, Veithen A, Springael JY, Sotiropoulou PA, Mendes Da Costa A, Miot F, et al. Stroma cell-derived factor-1a signaling enhances calcium transients and beating frequency in rat neonatal cardiomyocytes. PLoS One (2013) 8:e56007. doi:10.1371/journal.pone.0056007.
105. Myers SJ, Wong LM, Charo IF. Signal transduction and ligand specificity of the human monocyte chemoattractant protein-1 receptor in transfected embryonic kidney cells. J Biol Chem (1995) 270:5786-92. doi:10.1074/jbc.270.11.5786.
106. Mukherjee D, Zhao J. The role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res (2013) 3:46-57.
107. Hamm HE. The many faces of G protein signaling. J Biol Chem (1998) 273:669-72. doi:10.1074/jbc.273.2.669.
108. Goldsmith ZG, Dhanasekaran DN. G Protein regulation of MAPK networks. Oncogene (2007) 26:3122-42. doi:10.1038/sj.onc.1210407.
109. Louwette S, Van Geet C, Freson K. Regulators of G protein signaling: role in hematopoiesis, megakaryopoiesis and platelet function. J Thromb Haemost (2012) 10:2215-22. doi:10.1111/j.1538-7836.2012.04903.x.
110. Preininger AM, Hamm HE. G protein signaling: insights from new structures. Sci STKE (2004) 2004:re3. doi:10.1126/stke.2182004re3.
111. Watson N, Linder ME, Druey KM, Kehrl JH, Blumer KJ. RGS family members: GTPase-activating proteins for heterotrimeric G-protein alpha-subunits. Nature (1996) 383:172-5. doi:10.1038/383172a0.
112. Berthebaud M. RGS16 is a negative regulator of SDF-1-CXCR4 signaling in megakaryocytes. Blood (2005) 106:2962-8. doi:10.1182/blood-2005-02-0526.
113. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal (2009) 2:ra81. doi:10.1126/scisignal.2000610.
114. Vila-Coro AJ, Rodriguez-Frade JM, Martin De Ana A, Moreno-Ortiz MC, Martinez-A C, Mellado M. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J (1999) 13:1699-710.
115. Soriano SF, Serrano A, Hernanz-Falcón P, Ana AMD, Monterrubio M, Martínez-a C, et al. Chemokines integrate JAK/STAT and G-protein pathways during chemotaxis and calcium flux responses. Eur J Immunol (2003) 33:1328-33. doi:10.1002/eji.200323897.
116. Shukla AK, Xiao K, Lefkowitz RJ. Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem Sci (2011) 36:457-69. doi:10.1016/j.tibs.2011.06.003.
117. Dewire SM, Ahn S, Lefkowitz RJ, Shenoy SK. β-arrestins and cell signaling. Annu Rev Physiol (2007) 69:483-510. doi:10.1146/annurev.physiol.69.022405.154749.
118. Zhang Y, Foudi A, Geay J-F, Berthebaud M, Buet D, Jarrier P, et al. Intracellular localization and constitutive endocytosis of CXCR4 in human CD34 + hematopoietic progenitor cells. Stem Cells (2004) 22:1015-29. doi:10.1634/stemcells.22-6-1015.
119. Pelekanos RA, Ting MJ, Sardesai VS, Ryan JM, Lim Y-C, Chan JKY, et al. Intracellular trafficking and endocytosis of CXCR4 in fetal mesenchymal stem/stromal cells. BMC Cell Biol (2014) 15:15. doi:10.1186/1471-2121-15-15.
120. Luttrell LM. Arrestin-dependent formation of 2 adrenergic receptor-Src protein kinase complexes. Science (1999) 283:655-61. doi:10.1126/science.283.5402.655.
121. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, et al. Beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem (2006) 281:1261-73. doi:10.1074/jbc. M506576200.
122. Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev (2010) 29:709-22. doi:10.1007/s10555-010-9256-x.
123. Decaillot FM, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP, Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J Biol Chem (2011) 286:32188-97. doi:10.1074/jbc. M111.277038.
124. Uto-Konomi A, McKibben B, Wirtz J, Sato Y, Takano A, Nanki T, et al. CXCR7 agonists inhibit the function of CXCL12 by down-regulation of CXCR4. Biochem Biophys Res Commun (2013) 431:772-6. doi:10.1016/j.bbrc.2013.01.032.
125. Panetta R, Greenwood MT. Physiological relevance of GPCR oligomerization and its impact on drug discovery. Drug Discov Today (2008) 13:1059-66. doi:10.1016/j.drudis.2008.09.002.
126. Babcock GJ, Farzan M, Sodroski J. Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor. J Biol Chem (2003) 278:3378-85. doi:10.1074/jbc. M210140200.
127. Hamatake M, Aoki T, Futahashi Y, Urano E, Yamamoto N, Komano J. Ligand-independent higher-order multimerization of CXCR4, a G-protein-coupled chemokine receptor involved in targeted metastasis. Cancer Sci (2009) 100:95-102. doi:10.1111/j.1349-7006.2008.00997.x.
128. Toth PT, Ren D, Miller RJ. Regulation of CXCR4 receptor dimerization by the chemokine SDF-1alpha and the HIV-1 coat protein gp120: a fluorescence resonance energy transfer (FRET) study. J Pharmacol Exp Ther (2004) 310:8-17. doi:10.1124/jpet.103.064956.
129. Ray P, Lewin SA, Mihalko LA, Lesher-Perez SC, Takayama S, Luker KE, et al. Secreted CXCL12 (SDF-1) forms dimers under physiological conditions. Biochem J (2012) 442:433-42. doi:10.1042/BJ20111341.
130. Drury LJ, Ziarek JJ, Gravel S, Veldkamp CT, Takekoshi T, Hwang ST, et al. Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc Natl Acad Sci U S A (2011) 108:17655-60. doi:10.1073/pnas.1101133108.
131. Schwartz V, Lue H, Kraemer S, Korbiel J, Krohn R, Ohl K, et al. A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett (2009) 583:2749-57. doi:10.1016/j.febslet.2009.07.058.
132. Rodríguez-Frade JM, Del Real G, Serrano A, Hernanz-Falcón P, Soriano SF, Vila-Coro AJ, et al. Blocking HIV-1 infection via CCR5 and CXCR4 receptors by acting in trans on the CCR2 chemokine receptor. EMBO J (2004) 23:66-76. doi:10.1038/sj.emboj.7600020.
133. Wang J, Alvarez R, Roderiquez G, Guan E, Norcross MA. Constitutive association of cell surface CCR5 and CXCR4 in the presence of CD4. J Cell Biochem (2004) 93:753-60. doi:10.1002/jcb.20161.
134. Percherancier Y, Berchiche YA, Slight I, Volkmer-Engert R, Tamamura H, Fujii N, et al. Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo-and heterodimers. J Biol Chem (2005) 280:9895-903. doi:10.1074/jbc. M411151200.
135. Sohy D, Parmentier M, Springael J-Y. Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J Biol Chem (2007) 282:30062-9. doi:10.1074/jbc. M705302200.
136. Contento RL, Molon B, Boularan C, Pozzan T, Manes S, Marullo S, et al. CXCR4-CCR5: a couple modulating T cell functions. Proc Natl Acad Sci U S A (2008) 105:10101-6. doi:10.1073/pnas.0804286105.
137. Isik N, Hereld D, Jin T. Fluorescence resonance energy transfer imaging reveals that chemokine-binding modulates heterodimers of CXCR4 and CCR5 receptors. PLoS One (2008) 3:e3424. doi:10.1371/journal.pone.0003424.
138. Kremer KN, Clift IC, Miamen AG, Bamidele AO, Qian N-X, Humphreys TD, et al. Stromal cell-derived factor-1 signaling via the CXCR4-TCR heterodimer requires phospholipase C-β3 and phospholipase C-γ1 for distinct cellular responses. J Immunol (2011) 187:1440-7. doi:10.4049/jimmunol.1100820.
139. Kremer KN, Kumar A, Hedin KE. Gai2 and ZAP-70 mediate RasGRP1 membrane localization and activation of SDF-1-induced T cell functions. J Immunol (2011) 187:3177-85. doi:10.4049/jimmunol.1100206.
140. Patrussi L, Ulivieri C, Lucherini OM, Paccani SR, Gamberucci A, Lanfrancone L, et al. p52Shc is required for CXCR4-dependent signaling and chemotaxis in T cells. Blood (2007) 110:1730-8. doi:10.1182/blood-2007-01-068411.
141. Wagner NM, Bierhansl L, Noldge-Schomburg G, Vollmar B, Roesner JP. Toll-like receptor 2-blocking antibodies promote angiogenesis and induce ERK1/2 and AKT signaling via CXCR4 in endothelial cells. Arterioscler Thromb Vasc Biol (2013) 33:1943-51. doi:10.1161/ATVBAHA.113.301783.
142. Hsiao JJ, Ng BH, Smits MM, Wang J, Jasavala RJ, Martinez HD, et al. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility. BMC Cancer (2015) 15:204. doi:10.1186/s12885-015-1201-5.
143. Tripathi A, Vana PG, Chavan TS, Brueggemann LI, Byron KL, Tarasova NI, et al. Heteromerization of chemokine (C-X-C motif) receptor 4 with a 1A/B-adrenergic receptors controls a 1-adrenergic receptor function. Proc Natl Acad Sci U S A (2015) 112:1659-E1668. doi:10.1073/pnas.1417564112.
144. Kraemer S, Alampour-Rajabi S, El Bounkari O, Bernhagen J. Hetero-oligomerization of chemokine receptors: diversity and relevance for function. Curr Med Chem (2013) 20:2524-36. doi:10.2174/09298673113209990117.
145. Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med (2012) 209:551-63. doi:10.1084/jem.20111739.
146. Roger T, Froidevaux C, Martin C, Calandra T. Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of toll-like receptor 4 (TLR4). J Endotoxin Res (2003) 9:119-23. doi:10.1177/09680519030090020801.
147. Santos LL, Morand EF. Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis. Clin Chim Acta (2009) 399:1-7. doi:10.1016/j.cca.2008.09.014.
148. De Souza HS, Tortori CA, Lintomen L, Figueiredo RT, Bernardazzi C, Leng L, et al. Macrophage migration inhibitory factor promotes eosinophil accumulation and tissue remodeling in eosinophilic esophagitis. Mucosal Immunol (2015). doi:10.1038/mi.2015.6.
149. Kouzoukas DE, Meyer-Siegler KL, Ma F, Westlund KN, Hunt DE, Vera PL. Macrophage migration inhibitory factor mediates PAR-induced bladder pain. PLoS One (2015) 10:e0127628. doi:10.1371/journal.pone.0127628.
150. Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R, et al. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature (2008) 451:578-82. doi:10.1038/nature06504.
151. Stoppe C, Werker T, Rossaint R, Dollo F, Lue H, Wonisch W, et al. What is the significance of perioperative release of macrophage migration inhibitory factor in cardiac surgery? Antioxid Redox Signal (2013) 19:231-9. doi:10.1089/ars.2012.5015.
152. Goetzenich A, Kraemer S, Rossaint R, Bleilevens C, Dollo F, Siry L, et al. The role of macrophage migration inhibitory factor in anesthetic-induced myocardial preconditioning. PLoS One (2014) 9:e92827. doi:10.1371/journal.pone.0092827.
153. Heinrichs D, Berres ML, Coeuru M, Knauel M, Nellen A, Fischer P, et al. Protective role of macrophage migration inhibitory factor in nonalcoholic steatohepatitis. FASEB J (2014) 28:5136-47. doi:10.1096/fj.14-256776.
154. Arno B, Grassivaro F, Rossi C, Bergamaschi A, Castiglioni V, Furlan R, et al. Neural progenitor cells orchestrate microglia migration and positioning into the developing cortex. Nat Commun (2014) 5:5611. doi:10.1038/ncomms6611.
155. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, et al. MIF signal transduction initiated by binding to CD74. J Exp Med (2003) 197:1467-76. doi:10.1084/jem.20030286.
156. Shi X, Leng L, Wang T, Wang W, Du X, Li J, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity (2006) 25:595-606. doi:10.1016/j.immuni.2006.08.020.
157. Gore Y, Starlets D, Maharshak N, Becker-Herman S, Kaneyuki U, Leng L, et al. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem (2008) 283:2784-92. doi:10.1074/jbc. M703265200.
158. Cho Y, Crichlow GV, Vermeire JJ, Leng L, Du X, Hodsdon ME, et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci U S A (2010) 107:11313-8. doi:10.1073/pnas.1002716107.
159. Simons D, Grieb G, Hristov M, Pallua N, Weber C, Bernhagen J, et al. Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment. J Cell Mol Med (2011) 15:668-78. doi:10.1111/j.1582-4934.2010.01041.x.
160. Shin HN, Moon HH, Ku JL. Stromal cell-derived factor-1alpha and macrophage migration-inhibitory factor induce metastatic behavior in CXCR4-expressing colon cancer cells. Int J Mol Med (2012) 30:1537-43. doi:10.3892/ijmm.2012.1141.
161. Klasen C, Ohl K, Sternkopf M, Shachar I, Schmitz C, Heussen N, et al. MIF promotes B cell chemotaxis through the receptors CXCR4 and CD74 and ZAP-70 signaling. J Immunol (2014) 192:5273-84. doi:10.4049/jimmunol.1302209.
162. Lourenco S, Teixeira VH, Kalber T, Jose RJ, Floto RA, Janes SM. Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors. J Immunol (2015) 194:3463-74. doi:10.4049/jimmunol.1402097.
163. Vera PL, Iczkowski KA, Wang X, Meyer-Siegler KL. Cyclophosphamide-induced cystitis increases bladder CXCR4 expression and CXCR4-macrophage migration inhibitory factor association. PLoS One (2008) 3:e3898. doi:10.1371/journal.pone.0003898.
164. Wang H, Kadlecek TA, Au-Yeung BB, Goodfellow HE, Hsu LY, Freedman TS, et al. ZAP-70: an essential kinase in T-cell signaling. Cold Spring Harb Perspect Biol (2010) 2:a002279. doi:10.1101/cshperspect.a002279.
165. Lin YP, Cheng YJ, Huang JY, Lin HC, Yang BC. Zap70 controls the interaction of talin with integrin to regulate the chemotactic directionality of T-cell migration. Mol Immunol (2010) 47:2022-9. doi:10.1016/j.molimm.2010.04.011.
166. Dessein AF, Stechly L, Jonckheere N, Dumont P, Monte D, Leteurtre E, et al. Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells. Cancer Res (2010) 70:4644-54. doi:10.1158/0008-5472.CAN-09-3828.
167. Zhu G, Tang Y, Geng N, Zheng M, Jiang J, Li L, et al. HIF-alpha/MIF and NF-kappaB/IL-6 axes contribute to the recruitment of CD11b+Gr-1+ myeloid cells in hypoxic microenvironment of HNSCC. Neoplasia (2014) 16:168-79. doi:10.1593/neo.132034.
168. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 25:911-20. doi:10.1038/nbt1323.
169. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 13:23-35. doi:10.1016/j.ccr.2007.12.004.
170. Li J, Mo HY, Xiong G, Zhang L, He J, Huang ZF, et al. Tumor microenvironment macrophage inhibitory factor directs the accumulation of interleukin-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients. J Biol Chem (2012) 287:35484-95. doi:10.1074/jbc. M112.367532.
171. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 114:1141-9. doi:10.1182/blood-2009-03-208249.
172. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol (2009) 50:980-9. doi:10.1016/j.jhep.2008.12.033.
173. Schwartz V, Kruttgen A, Weis J, Weber C, Ostendorf T, Lue H, et al. Role for CD74 and CXCR4 in clathrin-dependent endocytosis of the cytokine MIF. Eur J Cell Biol (2012) 91:435-49. doi:10.1016/j.ejcb.2011.08.006.
174. Lue H, Dewor M, Leng L, Bucala R, Bernhagen J. Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74. Cell Signal (2011) 23:135-44. doi:10.1016/j.cellsig.2010.08.013.
175. George M, Vaughan JH. In vitro cell migration as a model for delayed hypersensitivity. Proc Soc Exp Biol Med (1962) 111:514-21. doi:10.3181/00379727-111-27841.
176. David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A (1966) 56:72-7. doi:10.1073/pnas.56.1.72.
177. Hermanowski-Vosatka A, Mundt SS, Ayala JM, Goyal S, Hanlon WA, Czerwinski RM, et al. Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis and random migration. Biochemistry (1999) 38:12841-9. doi:10.1021/bi991352p.
178. Dicosmo-Ponticello CJ, Hoover D, Coffman FD, Cohen S, Cohen MC. MIF inhibits monocytic movement through a non-canonical receptor and disruption of temporal Rho GTPase activities in U-937 cells. Cytokine (2014) 69:47-55. doi:10.1016/j.cyto.2014.05.005.
179. Yuan J, Wang J, Crain K, Fearns C, Kim KA, Hua KL, et al. Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4+ T cell resistance and enrichment. Mol Ther (2012) 20:849-59. doi:10.1038/mt.2011.310.
180. Penela P, Murga C, Ribas C, Tutor AS, Peregrin S, Mayor F Jr. Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease. Cardiovasc Res (2006) 69:46-56. doi:10.1016/j.cardiores.2005.09.011.
181. Okada M, Miyazaki S, Hirasawa Y. Increase in plasma concentration of ubiquitin in dialysis patients: possible involvement in beta 2-microglobulin amyloidosis. Clin Chim Acta (1993) 220:135-44. doi:10.1016/0009-8981(93)90042-3.
182. Majetschak M, Zedler S, Hostmann A, Sorell LT, Patel MB, Novar LT, et al. Systemic ubiquitin release after blunt trauma and burns: association with injury severity, posttraumatic complications, and survival. J Trauma (2008) 64:586-96. doi:10.1097/TA.0b013e3181641bc5.
183. Daino H, Matsumura I, Takada K, Odajima J, Tanaka H, Ueda S, et al. Induction of apoptosis by extracellular ubiquitin in human hematopoietic cells: possible involvement of STAT3 degradation by proteasome pathway in interleukin 6-dependent hematopoietic cells. Blood (2000) 95:2577-85.
184. Majetschak M, Ponelies N, Hirsch T. Targeting the monocytic ubiquitin system with extracellular ubiquitin. Immunol Cell Biol (2006) 84:59-65. doi:10.1111/j.1440-1711.2005.01399.x.
185. Saini V, Romero J, Marchese A, Majetschak M. Ubiquitin receptor binding and signaling in primary human leukocytes. Commun Integr Biol (2010) 3:608-10. doi:10.4161/cib.3.6.13375.
186. Tripathi A, Saini V, Marchese A, Volkman BF, Tang WJ, Majetschak M. Modulation of the CXC chemokine receptor 4 agonist activity of ubiquitin through C-terminal protein modification. Biochemistry (2013) 52:4184-92. doi:10.1021/bi400254f.
187. Yan L, Cai Q, Xu Y. The ubiquitin-CXCR4 axis plays an important role in acute lung infection-enhanced lung tumor metastasis. Clin Cancer Res (2013) 19:4706-16. doi:10.1158/1078-0432.CCR-13-0011.
188. Tripathi A, Davis JD, Staren DM, Volkman BF, Majetschak M. CXC chemokine receptor 4 signaling upon co-activation with stromal cell-derived factor-1alpha and ubiquitin. Cytokine (2014) 65:121-5. doi:10.1016/j.cyto.2013.12.008.
189. Ralat LA, Kalas V, Zheng Z, Goldman RD, Sosnick TR, Tang WJ. Ubiquitin is a novel substrate for human insulin-degrading enzyme. J Mol Biol (2011) 406:454-66. doi:10.1016/j.jmb.2010.12.026.
190. Vlahakis SR, Algeciras-Schimnich A, Bou G, Heppelmann CJ, Villasis-Keever A, Collman RG, et al. Chemokine-receptor activation by env determines the mechanism of death in HIV-infected and uninfected T lymphocytes. J Clin Invest (2001) 107:207-15. doi:10.1172/JCI11109.
191. Hesselgesser J, Taub D, Baskar P, Greenberg M, Hoxie J, Kolson DL, et al. Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. Curr Biol (1998) 8:595-8. doi:10.1016/S0960-9822(98)70230-1.
192. Lopes De Campos WR, Chirwa N, London G, Rotherham LS, Morris L, Mayosi BM, et al. HIV-1 subtype C unproductively infects human cardiomyocytes in vitro and induces apoptosis mitigated by an anti-Gp120 aptamer. PLoS One (2014) 9:e110930. doi:10.1371/journal.pone.0110930.
193. Vlahakis SR, Villasis-Keever A, Gomez TS, Bren GD, Paya CV. Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4. J Infect Dis (2003) 188:1455-60. doi:10.1086/379738.
194. Endo M, Inatsu A, Hashimoto K, Takamune N, Shoji S, Misumi S. Human immunodeficiency virus-induced apoptosis of human breast cancer cells via CXCR4 is mediated by the viral envelope protein but does not require CD4. Curr HIV Res (2008) 6:34-42. doi:10.2174/157016208783571991.
195. Singh S, Bond VC, Powell M, Singh UP, Bumpers HL, Grizzle WE, et al. CXCR4-gp120-IIIB interactions induce caspase-mediated apoptosis of prostate cancer cells and inhibit tumor growth. Mol Cancer Ther (2009) 8:178-84. doi:10.1158/1535-7163.MCT-08-0643.
196. Blanco J, Jacotot E, Cabrera C, Cardona A, Clotet B, De Clercq E, et al. The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling. AIDS (1999) 13:909-17. doi:10.1097/00002030-199905280-00006.
197. Biard-Piechaczyk M, Robert-Hebmann V, Richard V, Roland J, Hipskind RA, Devaux C. Caspase-dependent apoptosis of cells expressing the chemokine receptor CXCR4 is induced by cell membrane-associated human immunodeficiency virus type 1 envelope glycoprotein (gp120). Virology (2000) 268:329-44. doi:10.1006/viro.1999.0151.
198. Trushin SA, Algeciras-Schimnich A, Vlahakis SR, Bren GD, Warren S, Schnepple DJ, et al. Glycoprotein 120 binding to CXCR4 causes p38-dependent primary T cell death that is facilitated by, but does not require cell-associated CD4. J Immunol (2007) 178:4846-53. doi:10.4049/jimmunol.178.8.4846.
199. Anand AR, Ganju RK. HIV-1 gp120-mediated apoptosis of T cells is regulated by the membrane tyrosine phosphatase CD45. J Biol Chem (2006) 281:12289-99. doi:10.1074/jbc. M511786200.
200. Ferri KF, Jacotot E, Leduc P, Geuskens M, Ingber DE, Kroemer G. Apoptosis of syncytia induced by the HIV-1-envelope glycoprotein complex: influence of cell shape and size. Exp Cell Res (2000) 261:119-26. doi:10.1006/excr.2000.5062.
201. Castedo M, Ferri KF, Blanco J, Roumier T, Larochette N, Barretina J, et al. Human immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/FKBP12-rapamycin-associated protein-mediated p53 phosphorylation. J Exp Med (2001) 194:1097-110. doi:10.1084/jem.194.8.1097.
202. Molina L, Grimaldi M, Robert-Hebmann V, Espert L, Varbanov M, Devaux C, et al. Proteomic analysis of the cellular responses induced in uninfected immune cells by cell-expressed X4 HIV-1 envelope. Proteomics (2007) 7:3116-30. doi:10.1002/pmic.200700306.
203. Denizot M, Varbanov M, Espert L, Robert-Hebmann V, Sagnier S, Garcia E, et al. HIV-1 gp41 fusogenic function triggers autophagy in uninfected cells. Autophagy (2008) 4:998-1008. doi:10.4161/auto.6880.
204. Wu CH, Wang CJ, Chang CP, Cheng YC, Song JS, Jan JJ, et al. Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors. J Med Chem (2015) 58(3):1452-65. doi:10.1021/jm501772w.
205. Libert F, Parmentier M, Lefort A, Dinsart C, Van Sande J, Maenhaut C, et al. Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science (1989) 244:569-72. doi:10.1126/science.2541503.
206. Liert F, Parmentier M, Lefort A, Dumont JE, Vassart G. Complete nucleotide sequence of a putative G protein coupled receptor: RDC1. Nucleic Acids Res (1990) 18:1917. doi:10.1093/nar/18.7.1917.
207. Heesen M, Berman MA, Charest A, Housman D, Gerard C, Dorf ME. Cloning and chromosomal mapping of an orphan chemokine receptor: mouse RDC1. Immunogenetics (1998) 47:364-70. doi:10.1007/s002510050371.
208. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med (2006) 203:2201-13. doi:10.1084/jem.20052144.
209. Naumann U, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, Zerwes HG, et al. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS One (2010) 5:e9175. doi:10.1371/journal.pone.0009175.
210. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A (2007) 104:15735-40. doi:10.1073/pnas.0610444104.
211. Salmaggi A, Maderna E, Calatozzolo C, Gaviani P, Canazza A, Milanesi I, et al. CXCL12, CXCR4 and CXCR7 expression in brain metastases. Cancer Biol Ther (2009) 8:1608-14. doi:10.4161/cbt.8.17.9202.
212. D'Alterio C, Consales C, Polimeno M, Franco R, Cindolo L, Portella L, et al. Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr Cancer Drug Targets (2010) 10:772-81. doi:10.2174/156800910793605839.
213. Rath D, Chatterjee M, Borst O, Muller K, Stellos K, Mack AF, et al. Expression of stromal cell-derived factor-1 receptors CXCR4 and CXCR7 on circulating platelets of patients with acute coronary syndrome and association with left ventricular functional recovery. Eur Heart J (2014) 35:386-94. doi:10.1093/eurheartj/eht448.
214. Wang Y, Li G, Stanco A, Long JE, Crawford D, Potter GB, et al. CXCR4 and CXCR7 have distinct functions in regulating interneuron migration. Neuron (2011) 69:61-76. doi:10.1016/j.neuron.2010.12.005.
215. Kumar R, Tripathi V, Ahmad M, Nath N, Mir RA, Chauhan SS, et al. CXCR7 mediated Gialpha independent activation of ERK and Akt promotes cell survival and chemotaxis in T cells. Cell Immunol (2012) 272:230-41. doi:10.1016/j.cellimm.2011.09.015.
216. Chen Q, Zhang M, Li Y, Xu D, Wang Y, Song A, et al. CXCR7 mediates neural progenitor cells migration to CXCL12 independent of CXCR4. Stem Cells (2015) 33(8):2574-85. doi:10.1002/stem.2022.
217. Ödemis V, Lipfert J, Kraft R, Hajek P, Abraham G, Hattermann K, et al. The presumed atypical chemokine receptor CXCR7 signals through Gi/o proteins in primary rodent astrocytes and human glioma cells. Glia (2012) 60:372-81. doi:10.1002/glia.22271.
218. Canals M, Scholten DJ, De Munnik S, Han MK, Smit MJ, Leurs R. Ubiquitination of CXCR7 controls receptor trafficking. PLoS One (2012) 7:e34192. doi:10.1371/journal.pone.0034192.
219. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood (2009) 113:6085-93. doi:10.1182/blood-2008-12-196618.
220. Luker KE, Steele JM, Mihalko LA, Ray P, Luker GD. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Oncogene (2010) 29:4599-610. doi:10.1038/onc.2010.212.
221. Puchert M, Engele J. The peculiarities of the SDF-1/CXCL12 system: in some cells, CXCR4 and CXCR7 sing solos, in others, they sing duets. Cell Tissue Res (2014) 355:239-53. doi:10.1007/s00441-013-1747-y.
222. Chatterjee M, Seizer P, Borst O, Schonberger T, Mack A, Geisler T, et al. SDF-1alpha induces differential trafficking of CXCR4-CXCR7 involving cyclophilin A, CXCR7 ubiquitination and promotes platelet survival. FASEB J (2014) 28:2864-78. doi:10.1096/fj.14-249730.
223. Ding BS, Cao Z, Lis R, Nolan DJ, Guo P, Simons M, et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature (2014) 505:97-102. doi:10.1038/nature12681.
224. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med (1998) 187:2009-21. doi:10.1084/jem.187.12.2009.
225. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity (2000) 12:121-7. doi:10.1016/S1074-7613(00)80165-X.
226. Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity (2012) 36:705-16. doi:10.1016/j.immuni.2012.05.008.
227. Singh AK, Arya RK, Trivedi AK, Sanyal S, Baral R, Dormond O, et al. Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev (2013) 24:41-9. doi:10.1016/j.cytogfr.2012.08.007.
228. Rupertus K, Sinistra J, Scheuer C, Nickels RM, Schilling MK, Menger MD, et al. Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer. Clin Exp Metastasis (2014) 31:447-59. doi:10.1007/s10585-014-9639-4.
229. Chatterjee M, Borst O, Walker B, Fotinos A, Vogel S, Seizer P, et al. Macrophage migration inhibitory factor (MIF) limits activation-induced apoptosis of platelets via CXCR7-dependent Akt signaling. Circ Res (2014) 115:939-49. doi:10.1161/CIRCRESAHA.115.305171.
230. Shimizu N, Soda Y, Kanbe K, Liu HY, Mukai R, Kitamura T, et al. A putative G protein-coupled receptor, RDC1, is a novel coreceptor for human and simian immunodeficiency viruses. J Virol (2000) 74:619-26. doi:10.1128/JVI.74.2.619-626.2000.
231. Chevigné A, Fievez V, Szpakowska M, Fischer A, Counson M, Plesséria J-M, et al. Neutralising properties of peptides derived from CXCR4 extracellular loops towards CXCL12 binding and HIV-1 infection. Biochim Biophys Acta (2014) 1843:1031-41. doi:10.1016/j.bbamcr.2014.01.017.
232. Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, Francois F, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet (2003) 34:70-4. doi:10.1038/ng1149.
233. Poty S, Desogere P, Goze C, Boschetti F, D'huys T, Schols D, et al. New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities. Dalton Trans (2015) 44:5004-16. doi:10.1039/c4dt02972k.
234. Wetzler M, Talpaz M, Kleinerman ES, King A, Huh YO, Gutterman JU, et al. A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med (1990) 89:663-72. doi:10.1016/0002-9343(90)90187-I.
235. McDermott DH, Gao J-L, Liu Q, Siwicki M, Martens C, Jacobs P, et al. Chromothriptic cure of WHIM syndrome. Cell (2015) 160:686-99. doi:10.1016/j.cell.2015.01.014.
236. Wald O. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics (2013) 3:26-33. doi:10.7150/thno.4922.
237. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia (2008) 23:43-52. doi:10.1038/leu.2008.299.
238. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A (2003) 100:13513-8. doi:10.1073/pnas.2235846100.
239. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation (2004) 110:3300-5. doi:10.1161/01.CIR.0000147780.30124.CF.
240. Chen J, Chemaly E, Liang L, Kho C, Lee A, Park J, et al. Effects of CXCR4 gene transfer on cardiac function after ischemia-reperfusion injury. Am J Pathol (2010) 176:1705-15. doi:10.2353/ajpath.2010.090451.
241. Liehn EA, Tuchscheerer N, Kanzler I, Drechsler M, Fraemohs L, Schuh A, et al. Double-edged role of the CXCL12/CXCR4 axis in experimental myocardial infarction. J Am Coll Cardiol (2011) 58:2415-23. doi:10.1016/j.jacc.2011.08.033.
242. Liehn EA, Kanzler I, Konschalla S, Kroh A, Simsekyilmaz S, Sonmez TT, et al. Compartmentalized protective and detrimental effects of endogenous macrophage migration-inhibitory factor mediated by CXCR2 in a mouse model of myocardial ischemia/reperfusion. Arterioscler Thromb Vasc Biol (2013) 33:2180-6. doi:10.1161/ATVBAHA.113.301633.
243. Rex S, Kraemer S, Grieb G, Emontzpohl C, Soppert J, Goetzenich A, et al. The role of macrophage migration inhibitory factor in critical illness. Mini Rev Med Chem (2014) 14:1116-24.
244. Dipersio JF, Uy GL, Yasothan U, Kirkpatrick P. Plerixafor. Nat Rev Drug Discov (2009) 8:105-7. doi:10.1038/nrd2819.
245. Pusic I, Dipersio JF. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Curr Opin Hematol (2010) 17:319-26. doi:10.1097/MOH.0b013e328338b7d5.
246. Hsu W-T, Jui H-Y, Huang Y-H, Su M-YM, Wu Y-W, Tseng W-YI, et al. CXCR4 antagonist TG-0054 mobilizes mesenchymal stem cells, attenuates inflammation, and preserves cardiac systolic function in a porcine model of myocardial infarction. Cell Transplant (2014) 24:1313-28. doi:10.3727/096368914X681739.
247. Hatse S, Princen K, De Clercq E, Rosenkilde MM, Schwartz TW, Hernandez-Abad PE, et al. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol (2005) 70:752-61. doi:10.1016/j.bcp.2005.05.035.
248. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol (2009) 75:1240-7. doi:10.1124/mol.108.053389.
249. Zernecke A, Schober A, Bot I, Von Hundelshausen P, Liehn EA, Mopps B, et al. SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res (2005) 96:784-91. doi:10.1161/01.RES.0000162100.52009.38.
250. Noels H, Zhou B, Tilstam PV, Theelen W, Li X, Pawig L, et al. Deficiency of endothelial CXCR4 reduces reendothelialization and enhances neointimal hyperplasia after vascular injury in atherosclerosis-prone mice. Arterioscler Thromb Vasc Biol (2014) 34:1209-20. doi:10.1161/ATVBAHA.113.302878.